HR Execs on the Move

Repligen Corp

www.repligen.com

 
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.repligen.com
  • 41 Seyon St Ste 100
    Waltham, MA USA 02453
  • Phone: 781.250.0111

Executives

Name Title Contact Details
Olivier Loeillot
President and Chief Commercial Officer Profile
Travis Harkness
Vice President Supply Chain and Analytics Profile
Travis Ward
Director of R&D Profile
Derek Carroll
Director of R&D Profile
Christine Gebski
Vice President, Product Management and Field Applications Profile

Similar Companies

Relay Technology Management

Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs.

Zucara Therapeutics

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.

Proventys

Proventys, Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.